Serum erythropoietin levels in paroxysmal nocturnal haemoglobinuria: implications for therapy.
In order to assess the rationale and possible indications for the use of recombinant erythropoietin in paroxysmal nocturnal haemoglobinuria (PNH), we have measured endogenous erythropoietin (Epo) levels in 18 patients with PNH and in 44 patients with iron deficiency anaemia (IDA). In both groups of patients we found a significant inverse correlation between Epo and haemoglobin (Hb). However, the mean Epo level was significantly higher in the PNH group (385 mU/ml) than in the IDA group (136 mU/ml). The range of Epo levels at any given Hb was greater in the PNH group than in the IDA group. There was a significant positive correlation between Epo and absolute reticulocyte count. Since Epo administration is unlikely to benefit patients with high levels of endogenous Epo, we conclude that in the majority of patients with PNH there is no indication for treatment with Epo.
McMullin
M F
MF
The Queen's University of Belfast, Northern Ireland.
Hillmen
P
P
Elder
G E
GE
Lappin
T R
TR
Luzzatto
L
L
D004921:Erythropoietin / Q000097:blood*; D006454:Hemoglobins / Q000032:analysis; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood* / Q000628:therapy; D006801:Humans; D007501:Iron / Q000627:therapeutic use
D006454:Hemoglobins; D004921:Erythropoietin; D007501:Iron